VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis.
ADAMTS13:AC
AKI outcomes
Prediction
VWF:Ag
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
20 Jan 2024
20 Jan 2024
Historique:
received:
19
09
2023
accepted:
18
12
2023
medline:
20
1
2024
pubmed:
20
1
2024
entrez:
20
1
2024
Statut:
aheadofprint
Résumé
We investigated the von Willebrand factor to ADAMTS13 ratio (von Willebrand factor [VWF]:Ag/ADAMTS13:AC) as a potential biomarker for the outcomes of acute kidney injury (AKI) in liver cirrhosis (LC). This retrospective cross-sectional study included patients with LC who developed AKI (AKI group: n = 91) and patients with LC who did not develop AKI [non-AKI (NAKI) group, n = 91] as a control group. Plasma levels of the von Willebrand factor antigen (Ag) and ADAMTS13 activity (AC) were measured in patients with AKI or NAKI. Moreover, risk factors for onset of AKI, AKI-associated 90-day mortality, and poor AKI treatment response were identified. The AKI group had a significantly higher VWF:Ag/ADAMTS13:AC than the NAKI group. Values of VWF:Ag/ADAMTS13:AC ≥ 5.7 were identified as risk factors for AKI onset in patients with LC (odds ratio [OR] 2.56; 95% CI 1.26-4.99; p < 0.001). Among patients with AKI, values of VWF:Ag/ADAMTS13:AC ≥ 9.0 were identified as risk factors for 90-day mortality (OR 6.83; 95% CI 2.32-20.10; p < 0.001). Cumulative survival was significantly lower in those with high (≥ 9.0) than in those with low (< 9.0) VWF:Ag/ADAMTS13:AC. Furthermore, values of VWF:Ag/ADAMTS13:AC ≥ 7.4 were identified as risk factors for poor treatment response (OR 4.2; 95% CI 1.39-12.70; p < 0.001). The treatment response rates were significantly higher in those with low (< 7.4) VWF:Ag/ADAMTS13:AC than in those with high (≥ 7.4) VWF:Ag/ADAMTS13:AC. VWF:Ag/ADAMTS13:AC potentially predicts the onset, prognosis, and treatment response of AKI in patients with LC.
Identifiants
pubmed: 38244124
doi: 10.1007/s10620-023-08257-w
pii: 10.1007/s10620-023-08257-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 22fk0210097h0002
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Allegretti AS, Parada XV, Endres P et al. Urinary NGAL as a diagnostic and prognostic marker for acute kidney injury in cirrhosis: a prospective study. Clin Transl Gastroenterol 2021;12:e00359.
pubmed: 33979307
pmcid: 8116001
Ng CK, Chan MH, Tai MH et al. Hepatorenal syndrome. Clin Biochem Rev 2007;28:11–17.
pubmed: 17603637
pmcid: 1904420
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–460.
Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008;48:2064–2077.
pubmed: 19003880
Tariq R, Hadi Y, Chahal K et al. Incidence, mortality and predictors of acute kidney injury in patients with cirrhosis: a systematic review and meta-analysis. J Clin Transl Hepatol. 2020;8:135–142.
pubmed: 32832393
pmcid: 7438348
Patidar KR, Naved MA, Grama A et al. Acute kidney disease is common and associated with poor outcomes in patients with cirrhosis and acute kidney injury. J Hepatol. 2022;77:108–115.
pubmed: 35217065
Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis. Hepatology. 2013;57:1651–3.
pubmed: 23463403
Karagozian R, Bhardwaj G, Wakefield DB et al. Acute kidney injury is associated with higher mortality and healthcare costs in hospitalized patients with cirrhosis. Ann Hepatol. 2019;18:730–735.
pubmed: 31175020
Scott RA, Austin AS, Kolhe NV et al. Acute kidney injury is independently associated with death in patients with cirrhosis. Frontline Gastroenterol. 2013;4:191–197.
pubmed: 24660054
pmcid: 3955898
Angeli P, Gines P, Wong F et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968–974.
pubmed: 25638527
Angeli P, Gines P, Wong F et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64:531–537.
pubmed: 25631669
Cullaro G, Park M, Lai JC. “Normal” creatinine levels predict persistent kidney injury and waitlist mortality in outpatients with cirrhosis. Hepatology. 2018;68:1953–1960.
pubmed: 29698588
Salerno F, Guevara M, Bernardi M et al. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int. 2010;30:937–947.
pubmed: 20492521
Wong F. Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol. 2012;9:382–391.
pubmed: 22614754
Soejima K, Matsumoto M, Kokame K et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood. 2003;102:3232–3237.
pubmed: 12869506
Akyol O, Akyol S, Chen C-H. Update on ADAMTS13 and VWF in cardiovascular and hematological disorders. Clinica Chimica Acta. 2016;463:109–118.
Uemura M, Fujimura Y, Matsumoto M et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost. 2008;99:1019–1029.
pubmed: 18521503
Takaya H, Namisaki T, Asada S et al. ADAMTS13, VWF, and endotoxin are interrelated and associated with the severity of liver cirrhosis via hypercoagulability. J Clin Med. 2022;11:1835.
pubmed: 35407443
pmcid: 8999602
Simbrunner B, Villesen IF, Scheiner B et al. Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome. Hepatol Int. 2023;17:1532–1544.
pubmed: 37605068
Takaya H, Namisaki T, Enomoto M et al. The ratio of von Willebrand factor antigen to ADAMTS13 activity: usefulness as a prognostic biomarker in acute-on-chronic liver failure. Biology. 2023;12:164.
pubmed: 36829443
pmcid: 9952680
Sedaghat S, de Vries PS, Boender J et al. von Willebrand factor, ADAMTS13 activity, and decline in kidney function: a population-based cohort study. Am J Kidney Dis. 2016;68:726–732.
pubmed: 27497525
Tsai HM. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. Kidney Int Suppl. 2009;75:S11–S14.
Hametner S, Ferlitsch A, Ferlitsch M et al. The VITRO score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a new marker for clinically significant portal hypertension in comparison to other non-invasive parameters of fibrosis including ELF test. PLoS ONE. 2016;11:e0149230.
pubmed: 26895398
pmcid: 4760704
Yewale RV, Ramakrishna BS. Novel biomarkers of acute kidney injury in chronic liver disease: where do we stand after a decade of research? Hepatol Res. 2023;53:3–17.
pubmed: 36262036
Lee HA, Seo YS. Current knowledge about biomarkers of acute kidney injury in liver cirrhosis. Clin Mol Hepatol. 2022;28:31–46.
pubmed: 34333958
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. Corrigendum to “EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis”. J Hepatol 2018;69:1207.
Yoshiji H, Nagoshi S, Akahane T et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol. 2021;56:593–619.
pubmed: 34231046
pmcid: 8280040
Yoshiji H, Nagoshi S, Akahane T et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res. 2021;51:725–749.
pubmed: 34228859
Crabb DW, Im GY, Szabo G et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71:306–333.
pubmed: 31314133
Henry BM, Benoit SW, de Oliveira MHS et al. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy. Int J Lab Hematol. 2021;43:129–136.
pubmed: 33270980
Tahata Y, Sakamori R, Maesaka K et al. Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis. Hepatol Res. 2023;53:301–311.
pubmed: 36507871
Maesaka K, Sakamori R, Yamada R et al. Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment. Hepatol Res. 2021;51:517–527.
pubmed: 33507588
Shibamoto A, Namisaki T, Suzuki J, et al. Hemoglobin levels as a surrogate marker of sarcopenia in patients with liver cirrhosis. Hepatol Res. 2023.
Kato S, Matsumoto M, Matsuyama T et al. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006;46:1444–1452.
pubmed: 16934083
Matsumoto M, Kawaguchi S, Ishizashi H et al. Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress. Pathophysiol Haemost Thromb. 2005;34:35–40.
pubmed: 16293984
Jung CY, Chang JW. Hepatorenal syndrome: current concepts and future perspectives. Clin Mol Hepatol. 2023.
Chaney A. A Review for the practicing clinician: hepatorenal syndrome, a form of acute kidney injury, in patients with cirrhosis. Clin Exp Gastroenterol. 2021;14:385–396.
pubmed: 34675586
pmcid: 8502008
Gracia-Sancho J, Marrone G, Fernandez-Iglesias A. Hepatic microcirculation and mechanisms of portal hypertension. Nat Rev Gastroenterol Hepatol. 2019;16:221–234.
pubmed: 30568278
Takaya H, Uemura M, Fujimura Y et al. ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score. Hepatol Res. 2012;42:459–472.
pubmed: 22292786
Uemura M, Fujimura Y, Ko S et al. Determination of ADAMTS13 and its clinical significance for ADAMTS13 supplementation therapy to improve the survival of patients with decompensated liver cirrhosis. Int J Hepatol. 2011;2011:759047.
pubmed: 21994870
pmcid: 3170842
Hugenholtz GC, Adelmeijer J, Meijers JC et al. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology. 2013;58:752–761.
pubmed: 23468040
Enomoto M, Takaya H, Namisaki T et al. Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute-on-chronic liver failure development and prognosis in patients with liver cirrhosis. Hepatol Res. 2022;52:390–400.
pubmed: 34964539
Jiang QQ, Han MF, Ma K et al. Acute kidney injury in acute-on-chronic liver failure is different from in decompensated cirrhosis. World J Gastroenterol. 2018;24:2300–2310.
pubmed: 29881239
pmcid: 5989244
Makris K, Spanou L. Acute kidney injury: definition, pathophysiology and clinical phenotypes. Clin Biochem Rev. 2016;37:85–98.
pubmed: 28303073
pmcid: 5198510
Wang Y, Liu LP, Bai WY et al. Renal haemodynamics in patients with liver cirrhosis assessed by colour ultrasonography. J Int Med Res. 2011;39:249–255.
pubmed: 21672328
Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest. 1977;37:635–642.
pubmed: 594643
Plautz WE, Haldeman SH, Dyer MR et al. Reduced cleavage of von willebrand factor by ADAMTS13 is associated with microangiopathic acute kidney injury following trauma. Blood Coagul Fibrinolysis. 2022;33:14–24.
pubmed: 34889809
Scheiner B, Balcar L, Nussbaumer RJ et al. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. J Hepatol. 2022;76:1090–1099.
pubmed: 35066090
Amin AA, Alabsawy EI, Jalan R et al. Epidemiology, pathophysiology, and management of hepatorenal syndrome. Semin Nephrol. 2019;39:17–30.
pubmed: 30606404